Objective: To study the expression of CD70 and the methylation level of CD70 promoter in immuno-related pancytopenia(IRP)patients, and explore the role of CD70 in the pathogenesis of IRP.
Methods: Thirty- five IRP patients and fifteen healthy donors were enrolled in this study. Peripheral blood mononuclear cells were isolated from venous blood by density gradient centrifugation, and CD4(+) T cells were isolated by immunomagnetic beads. The mRNA level and the percentage of CD70 of CD4(+) T cells were measured by real- time quantitative polymerase chain reaction(RT- PCR)and flow cytometry respectively. Methylation- Specific PCR(MSP)was performed to determine the methylation level of CD70 promoter.
Results: The percentage of CD70 expression on CD4(+) T cells of untreated IRP patients[(7.46±1.51)%]was significantly higher than that of recovered ones[(5.95±1.34)%]and normal controls[(1.83 ± 0.60)%], and that of recovered IRP patients was significantly higher than of normal controls(P<0.05). The relative expressions of CD70 mRNA in CD4(+) T cells were 2.314(0.200-6.084), 1.021(0.135-3.434), 0.353(0.008-2.258)in three groups respectively. The differences among untreated IRP patients, recovered IRP patients and normal controls were significant(P<0.05). The CD70 promoter methylation level in CD4(+) T cells of all IRP patients was significantly lower than that of normal controls (P<0.05). The expression of CD70 positively correlated to the ratio of CD5(+) B cells(r=0.533, P<0.01).
Conclusion: The overexpression of CD70 may lead to immunologic disarrangement of patients, which may play important role in the pathogenesis of IRP.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348269 | PMC |
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.08.008 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!